APRI (Aprinoia Therapeutics) Total Long-Term Assets: $2.84 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Total Long-Term Assets?

Aprinoia Therapeutics APRI Total Long-Term Assets is $2.84 Mil as of Dec. 2023.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Aprinoia Therapeutics's Total Long-Term Assets for the quarter that ended in Dec. 2023 was $2.84 Mil.

Aprinoia Therapeutics Total Long-Term Assets Related Terms

Aprinoia Therapeutics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Total Long-Term Assets Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Long-Term Assets
2.51 3.83 2.84

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Total Long-Term Assets 2.51 0.00 3.83 4.92 2.84

Aprinoia Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $2.84 Mil mean?
Aprinoia Therapeutics (APRI) has a Total Long-Term Assets of $2.84 Mil as of Dec. 2023. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Total Long-Term Assets too high?
Aprinoia Therapeutics' current Total Long-Term Assets is $2.84 Mil.
How does Aprinoia Therapeutics' Total Long-Term Assets compare to ?
Aprinoia Therapeutics' Total Long-Term Assets of $2.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Total Long-Term Assets is $2.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Total Long-Term Assets of $2.84 Mil. The current Total Long-Term Assets is $2.84 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Total Long-Term Assets is $2.84 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.